Novel atheroprotective therapies are needed to address the residual risk associated with atherothrombotic cardiovascular disease. In this Review, Drs deGoma and Rader discuss the mechanisms of HDL-targeted drugs, including agents that enhance or mimic apolipoprotein A-I activity, and summarize the development of these pharmacotherapies in preclinical and clinical studies.
- Emil M. deGoma
- Daniel J. Rader
